A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Description

The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.

Interventions

• Ipatasertib (Drug)
  Ipatasertib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Tiragolumab (Drug)
  Tiragolumab in combination with atezolizumab will be administered at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Atezolizumab (Drug)
  Atezolizumab will be administered as a monotherapy and in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants' discontinuation from the parent study.
• Tiragolumab and Atezolizumab (Drug)
  Tiragolumab and Atezolizumab in fixed dose combination administered intravenously (IV) at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Bevacizumab (Drug)
  Bevacizumab will be administered as a monotherapy or in combination with atezolizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Entrectinib (Drug)
  Entrectinib will be administered as a monotherapy at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Inavolisib (Drug)
  Inavolisib will be administered as a monotherapy or in combination at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.
• Divarasib (Drug)
  Divarasib will be administered as a monotherapy or in combination with atezolizumab or bevacizumab at the same dose, schedule, and with the same administration guidelines that were in effect at the time of participants discontinuation from the parent study.

Eligibility criteria

Conditions

Locations

• GHdC Site Les Viviers — Charleroi, Belgium
• AZ Groeninge — Kortrijk, Belgium
• UZ Leuven Gasthuisberg — Leuven, Belgium
• Princess Margaret Cancer Center — Toronto, Ontario, Canada
• Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology — Wuhan, Hubei, China
• First Affiliated Hospital of Medical College of Xi'an Jiaotong University — XI 'an City, Shaanxi Province, Shaanxi, China
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China
• Beijing Cancer Hospital — Beijing, China
• the First Hospital of Jilin University — Changchun, China
• West China Hospital of Sichuan University — Chengdu, China
• Cancer Center of Guangzhou Medical University — Guangzhou, China
• Nanfang Hospital, Southern Medical University — Guangzhou, China
• Zhejiang People's Hospital — Hangzhou, China
• Sir Run Run Shaw Hospital Zhejiang University — Hangzhou, China
• Zhejiang Cancer Hospital — Hangzhou, China
• Harbin Medical University Cancer Hospital — Harbin, China
• The Second Affiliated Hospital of Anhui Medical University — Hefei, China
• Meizhou People's Hospital — Meizhou, China
• The 1st Affiliated Hospital of Nanchang Unversity — Nanchang, China
• Jiangsu Province Hospital of Chinese Medicine — Nanjing, China
• Fudan University Shanghai Cancer Center — Shanghai, China
• Shanghai Geriatric Medical Center — Shanghai, China
• Tianjin Cancer Hospital — Tianjin, China
• First Affiliated Hospital of Medical College of Xi'an Jiaotong University — Xi'an, China
• The First Affiliated Hospital of Xiamen University — Xiamen, China
• The First Affiliated Hospital of Xinxiang Medical University — Xinxiang, China
• Henan Cancer Hospital — Zhengzhou, China
• Clinica CIMCA — San José, Costa Rica
• ICIMED Instituto de Investigación en Ciencias Médicas — San José, Costa Rica
• AP-HM- Hôpital de La Timone — Marseille, Bouches-du-Rhône, France
• Institut Bergonie — Bordeaux, France
• Centre Francois Baclesse — Caen, France
• Institut de Cancérologie de Bourgogne — Dijon, France
• Centre Leon Berard — Lyon, France
• Hopital de la Timone — Marseille, France
• Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque — Montpellier, France
• CHU de Nantes - Hotel Dieu — Nantes, France
• Institut de cancerologie du Gard — Nîmes, France
• Institut Curie — Paris, France
• Hopital Tenon — Paris, France
• ICO - Site René Gauducheau — Saint-Herblain, France
• Institut Claudius Regaud — Toulouse, France
• Gustave Roussy — Villejuif, France
• General Hospital "G.Papanikolaou" — Asvestochóri, Greece
• Metropolitan General Hospital — Cholargós, Greece
• National Cancer Center Hospital East — Chiba, Japan
• Kyushu University Hospital — Fukuoka, Japan
• Toranomon Branch Hospital — Kanagawa, Japan
• Yokohama City University Medical Center — Kanagawa, Japan
• Kanagawa Cancer Center — Kanagawa, Japan
• National Cancer Center Hospital East — Kashiwa-shi, Japan
• Saitama Cancer Center — Saitama, Japan
• NHO Kinki-Chuo Chest Medical Center — Sakaishi, Japan
• Centro Medico Culiacan SA de CV — Culiacán, Sinaloa, Mexico
• Medical Care & Research — Mérida, Yucatán, Mexico
• Consultorio de Especialidad en Urologia Privado — Durango, Mexico
• Uniwersyteckie Centrum Kliniczne — Gda?sk, Poland
• Szpital Wojewódzki im. Miko?aja Kopernika — Koszalin, Poland
• Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie — Warsaw, Poland
• Russian Scientific Center of Roentgenoradiology — Moscow, Moscow Oblast, Russia
• Moscow City Oncology Hospital #62 — Moscow, Moscow Oblast, Russia
• P.A. Herzen Oncological Inst. — Moscow, Moscow Oblast, Russia
• National Cancer Center — Goyang-si, South Korea
• CHA Bundang Medical Center — Gyeonggi-do, South Korea
• Seoul National University Bundang Hospital — Seongnam-si, South Korea
• Asan Medical Center — Seoul, South Korea
• Samsung Medical Center — Seoul, South Korea
• Taichung Veterans General Hospital — Taichung, Taiwan
• National Cheng Kung University Hospital — Tainan, Taiwan
• National Taiwan University Hospital — Taipei, Taiwan
• Chang Gung Memorial Hospital - Linkou — Taoyuan, Taiwan
• Chulalongkorn Hospital — Bangkok, Thailand
• Siriraj Hospital — Bangkok, Thailand
• Maharaj Nakorn Chiangmai Hospital — Chiang Mai, Thailand
• Arensia Exploratory Medicine - Ukraine — Kyiv, Ukraine
• Leicester Royal Infirmary — Leicester, United Kingdom
• Royal Marsden Hospital - Surrey — Surrey, United Kingdom